Navigation Links
BiOptix to highlight new 404pi instrument at European symposia
Date:11/1/2012

BOULDER, Colo., AMSTERDAM and VIENNA, Nov. 1, 2012 /PRNewswire/ -- BiOptix today announced that it would be highlighting the new BiOptix 404pi, the first commercially available SPR instrument to incorporate phase-based common path interferometry technology, at the Label Free Technologies Show in Amsterdam from November 1 - 3 as well as at the PEGS Europe Summit on November 6 – 8. 

"At the Label Free and PEGS Europe meetings, BiOptix will unveil new application data that demonstrates the value proposition of the upcoming BiOptix 404pi," noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix.  "We are excited to demonstrate how BiOptix Enhanced or Phase-based SPR differs from standard surface plasmon resonance detection methods in that BiOptix technology combines the high sensitivity of SPR with the high stability and lower noise of common path interferometry—utilizing an internal reference for increased sensitivity."

BiOptix technology allows for the simultaneous monitoring of multiple analytes in a single sample.  This new class of SPR instrumentation from BiOptix has been designed to measure protein/protein and protein-small molecule interactions (down to 100 Da) in a high-throughput 96/384 well platform utilizing 4 parallel channels rather than a single flow cell.     

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano.  BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at:  www.bioptix.com


'/>"/>
SOURCE BiOptix
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. BiOptix Participates in Leading Life Sciences Event BioWest 2012
2. BiOptix announces expansion of Board of Directors
3. AGU journal highlights -- 31 August 2012
4. Biomass characterization technology research highlighted in Industrial Biotechnology journal
5. Genetics Society of America’s GENETICS journal highlights for August 2012
6. AGU journal highlights -- 31 July 2012
7. New video series highlights the people who fuel Americas innovation pipeline
8. AGU Journal highlights -- July 16
9. Differences between human twins at birth highlight importance of intrauterine environment
10. Genetics Society of Americas Genetics journal highlights for July 2012
11. Highlighting molecular clues to the link between childhood maltreatment and later suicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer ... Research (OICR) are pleased to report that Fusion Pharmaceuticals ... with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) ... groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as ... ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... de novo clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure ... at home or in healthcare facilities during periods of rest. A lightweight, non-invasive ...
Breaking Biology Technology: